Pilot Study: Radiofrequency Ablation Of Resectable Non-Small Cell Lung Cancer
- Determine the acute effects of intraoperative radiofrequency tumor ablation (RFA) in
patients with resectable non-small cell lung cancer.
- Determine the treatment-related toxicity in patients treated with this therapy.
- Determine the dimensions of the RFA lesion produced by the ablation procedure in these
OUTLINE: Patients undergo intraoperative radiofrequency tumor ablation over 10-15 minutes
for each tumor immediately followed by tumor resection.
PROJECTED ACCRUAL: A maximum of 20 patients will be accrued for this study.
Primary Purpose: Treatment
Walter J. Scott, MD, FACS
Fox Chase Cancer Center
United States: Federal Government
|Fox Chase Cancer Center||Philadelphia, Pennsylvania 19111|